New Screening Strategy for Epigenetic Targets: European ScreeningPort Forms Strategic Alliance with Hypha

26-Oct-2010 - Germany

Hypha Discovery Ltd and European ScreeningPort GmbH (ESP) announced a collaboration to evaluate Hypha’s MycoDiverseTM natural products library in ESP’s in-house epigenetic target assay panel. Currently, ESP provides access to Hypha’s MycoDiverseTM screening library to customers as part of its academic screening services business. The extension of the agreement to cover comprehensive profiling of the MycoDiverseTM library against ESP’s own panel of epigenetic targets greatly increases the scope and quality of drug discovery services offered by both companies. In addition, there is the potential to generate significant value by the identification of potent, selective compounds.

ESP recently established an epigenetic enzyme profiling panel covering sirtuins and histone deacetylase targets. These high throughput assays have already been shown to perform well in screens against known drugs and lead-like synthetic compounds.

This new collaboration, which builds on the service offerings of both companies, will expose the MycoDiverseTM natural products library to multiple therapeutic targets implicated in a range of epigenetic-linked diseases including cancer, asthma, neurodegenerative and metabolic disorders. ESP know–how is positioned at the forefront of epigenetic assay design. The technology employs a luminescence-based readout, which while more resistant to the artefacts associated with fluorescence based assays, is also extremely sensitive at low enzyme concentrations, allowing rapid and cost effective assay development and screening.

https://www.analytica-world.com/en/news/125012/new-screening-strategy-for-epigenetic-targets-european-screeningport-forms-strategic-alliance-with-hypha.html